Cell-Permeating α -Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Succinate dehydrogenase (SDH) and fumarate hydratase (FH) are components of the tricarboxylic acid (TCA) cycle and tumor suppressors. Loss of SDH or FH induces pseudohypoxia, a major tumor-supporting event, which is the activation of hypoxia-inducible factor (HIF) under normoxia. In SDH- or FH-deficient cells, HIF activation is due to HIF1alpha stabilization by succinate or fumarate, respectively, either of which, when in excess, inhibits HIFalpha prolyl hydroxylase (PHD). To reactivate PHD, we focused on its substrate, alpha-ketoglutarate. We designed and synthesized cell-permeating alpha-ketoglutarate derivatives, which build up rapidly and preferentially in cells with a dysfunctional TCA cycle. This study shows that succinate- or fumarate-mediated inhibition of PHD is competitive and is reversed by pharmacologically elevating intracellular alpha-ketoglutarate. Introduction of alpha-ketoglutarate derivatives restores normal PHD activity and HIF1alpha levels to SDH-suppressed cells, indicating new therapy possibilities for the cancers associated with TCA cycle dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected cells accumulate high levels of fumarate or succinate, and manifest HIFα upregulation that can be corrected by exogenous 2-oxoglutarate (MacKenzie et al., 2007), supporting a mechanistic link through competitive inhibition of the PHDs.”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“Beyond VHL disease, deficiencies in mitochondrial Krebs cycle enzymes, including succinate dehydrogenase and fumarate hydratase, promote accumulation of metabolites that inhibit PHDs, consequently facilitating HIF-α accumulation [228,229].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [228]
In the citing paper
“In fact, the latter, at least in the context of SDH loss, can be reversed by the addition of a membrane-permeable form of α-ketoglutarate (MacKenzie et al., 2007).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as MacKenzie et al., 2007
Citations
Cites
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 2×
“PHDs hydroxylate proline residues on the oxygen-dependent degradation (ODD) domain of HIF , generating docking sites for pVHL—part of an E3 ubiquitin ligase complex that targets HIF for degradation (21, 22).”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“from the rate for converting [5-(3)H]glucose to (3)H2O, as previously described (3), without a glucose starvation step.”
MethodSelf-citationHIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060 · cited 1×
“Under normal oxygenation conditions (normoxia), hypoxiainducible factor alpha (HIF ) proteins (HIF1 and/or HIF2 ), which are the formation-limiting units of the HIF transcription factor heteromer, are constantly both synthesized and degraded, a process that maintains them in high availability but at a very low steady…”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“Moreover, it was suggested that, in vitro, fumarate is a better inhibitor of PHD than succinate ( 13 ).”
BackgroundRole of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943 · cited 1×
“Pseudohypoxia is probably a major cause of tumors associated with VHL mutations (15).”
BackgroundArchitecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927 · cited 1×
“The first suggested that reactive oxygen species (ROS) from an impaired complex II of the electron transport chain (18, 30) potentially inhibit PHDs (7).”
BackgroundPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865 · cited 1×
“Pseudohypoxia was also shown recently in tumor cells with mutations in fumarate hydratase (FH) or in any of three of the four subunits of succinate dehydrogenase (SDH), SDHB, SDHC, or SDHD (5, 8, 9, 19, 20 , 28).”
BackgroundCharacterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304982200 · Cited by 794 · cited 1×
“Although PHDs depend on oxygen for activity, their affinity for oxygen is low (Km 230 to 250 M), making them good oxygen sensors (11).”
BackgroundSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672 · cited 2×
“This possibility has far-reaching consequences, since pseudohypoxia due to mTor-mediated increased translation of HIF1 has been associated with several other tumors (16).”
BackgroundSelf-citation
Cited by
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Succinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
“Affected cells accumulate high levels of fumarate or succinate, and manifest HIFa upregulation that can be corrected by exogenous 2-oxoglutarate (MacKenzie et al., 2007), supporting a mechanistic link through competitive inhibition of the PHDs.”
BackgroundTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
D’Hulst, G., Soro-Arnaiz, I., Masschelein, E., Veys, K., Fitzgerald, G., Smeuninx, B., Kim, S., Deldicque, L., Blaauw, B., Carmeliet, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13889-6 · Cited by 2,310
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., Liu, L., Liu, Y., Yang, C., Xu, Y., et al. (2012) · Genes & Development · doi:10.1101/gad.191056.112 · Cited by 1,188
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Post-translational modifications in signal integration
Deribe, Y. L., Pawson, T., & Dikic, I. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1842 · Cited by 876
Glutaminolysis Activates Rag-mTORC1 Signaling
Durán, R. V., Oppliger, W., Robitaille, A. M., Heiserich, L., Skendaj, R., Gottlieb, E., & Hall, M. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.043 · Cited by 730
Metabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 720
The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR
Chin, R. M., Fu, X., Pai, M. Y., Vergnes, L., Hwang, H., Deng, G., Diep, S., Lomenick, B., Meli, V. S., Monsalve, G. C., et al. (2014) · Nature · doi:10.1038/nature13264 · Cited by 608
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Sciacovelli, M., Gonçalves, E., Johnson, T. I., Zecchini, V. R., da Costa, A. S. H., Gaude, E., Drubbel, A. V., Theobald, S. J., Abbo, S. R., Tran, M. G. B., et al. (2016) · Nature · doi:10.1038/nature19353 · Cited by 584
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Palmieri, E. M., Gonzalez-Cotto, M., Baseler, W. A., Davies, L. C., Ghesquière, B., Maio, N., Rice, C. M., Rouault, T. A., Cassel, T., Higashi, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14433-7 · Cited by 464
Metabolic and epigenetic regulation of T-cell exhaustion
Franco, F., Jaccard, A., Romero, P., Yu, Y.-R., & Ho, P.-C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 455
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy
Sullivan, L. B., Gui, D. Y., & Heiden, M. G. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.85 · Cited by 406
Bardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364
Oxygen, a source of life and stress
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.06.018 · Cited by 383
“which then represses dioxygenase activity creating a ‘‘pseudohypoxic’’ condition [41,42].”
BackgroundMetabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis
Daye, D., & Wellen, K. E. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.002 · Cited by 374
The Tricarboxylic Acid Cycle, an Ancient Metabolic Network with a Novel Twist
Mailloux, R. J., Bériault, R., Lemire, J., Singh, R., Chénier, D. R., Hamel, R. D., & Appanna, V. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000690 · Cited by 329
“It has recently been shown that KG can promote aerobic respiration and alleviate hypoxia [29].”
BackgroundSwain, A., Bambouskova, M., Kim, H., Andhey, P. S., Duncan, D., Auclair, K., Chubukov, V., Simons, D. M., Roddy, T. P., Stewart, K. M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0210-0 · Cited by 324
Reactive Oxygen Species in Cancer Stem Cells
Shi, X., Zhang, Y., Zheng, J., & Pan, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4529 · Cited by 325
“Hypoxia inducible factor-1a (HIF-1a) protein, a basic helixloop-helix-PAS (Per-ARNT-Sim)-type transcriptional regulator under hypoxia, is involved in the maintenance of HSCs. ROS production is paradoxically increased under hypoxia, probably via electron leakage from ubisemiquinone to molecular oxygen (11).”
BackgroundInfluentialMetabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
The Metabolic Theory of Pulmonary Arterial Hypertension
Paulin, R., & Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301130 · Cited by 314
“For example, the inhibition of Kv channels (activated by increased mROS and inhibited by decreased mROS) causes plasmalemmal depolarization, resulting in increased influx of Ca2+, which promotes constriction and proliferation.86 H 2 O 2 can also regulate redox-sensitive components of the transcription machinery of the…”
BackgroundThe Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences
Cyr, A. R., & Domann, F. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3492 · Cited by 297
Ippolito, L., Morandi, A., Taddei, M. L., Parri, M., Comito, G., Iscaro, A., Raspollini, M. R., Magherini, F., Rapizzi, E., Masquelier, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0805-7 · Cited by 287
“Thus, we investigated whether CAF-driven lactate entry and its mitochondrial exploitation ( via succinate accumulation) could be involved in promoting HIF-1 levels through pyruvate/succinate competitive actions linked to PHDs inhibition [21].”
BackgroundCollagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
The functional roles of TCA cycle metabolites in cancer
Eniafe, J., & Jiang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01639-8 · Cited by 273
“mulation reverts pseudohypoxia and is accompanied by a plummeting of cancer cell proliferation [72, 73].”
BackgroundThe Metabolic Basis of Pulmonary Arterial Hypertension
Sutendra, G., & Michelakis, E. D. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.004 · Cited by 268
Mitochondria in cancer: Not just innocent bystanders
Frezza, C., & Gottlieb, E. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.008 · Cited by 268
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
“Moreover, HIF1a inhibition either with a cell-permeable esterified form of a-ketoglutarate (1-trifluoromethylbenzyl-a-ketoglutarate, TaKG), which reverses HIF1a stabilization by restoring PHD enzymatic activity (MacKenzie et al., 2007; Tennant et al., 2009), or with RNAi on HIF1a or HIF1b, the latter being the stable…”
BackgroundPyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Sutendra, G., & Michelakis, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00038 · Cited by 262
“For example αKG is a product of isocitrate dehydrogenase (IDH; a Krebs’ cycle enzyme) and can leak out of the mitochondria where it also serves as an important co-factor for the proline hydroxylases (PHD) that destabilize HIF (MacKenzie et al., 2007).”
BackgroundInfluentialMetabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & San Martin, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 259
“Reduced α-KG slows down hydroxylation reactions involving PHDs, resulting in HIF1α accumulation [3].”
BackgroundBroekgaarden, M., Weijer, R., van Gulik, T. M., Hamblin, M. R., & Heger, M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9588-7 · Cited by 255
“PHDs to inhibit HIF-1 regardless of intracellular oxygen tension [141].”
BackgroundInfluentialMetabolic basis to Sherpa altitude adaptation
Horscroft, J. A., Kotwica, A. O., Laner, V., West, J. A., Hennis, P. J., Levett, D. Z. H., Howard, D. J., Fernandez, B. O., Burgess, S. L., Ament, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700527114 · Cited by 247
“α-ketoglutarate plays regulatory roles in hypoxia, including a suppression ofHIF stabilization (35), but also supporting glutathione synthesis (36).”
BackgroundThe glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications
Xiao, D., Zeng, L., Yao, K., Kong, X., Wu, G., & Yin, Y. (2016) · Amino Acids · doi:10.1007/s00726-016-2254-8 · Cited by 246
“Therefore, AKG has been identified as a component for new possible therapy in treating cancers (MacKenzie et al. 2007).”
BackgroundSutendra, G., Bonnet, S., Rochefort, G., Haromy, A., Folmes, K. D., Lopaschuk, G. D., Dyck, J. R. B., & Michelakis, E. D. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001327 · Cited by 245
“Metabolic signals [mROS (33), the diffusible Krebs cycle product a-ketoglutarate (34), and GSK-3b (35)] also regulate HIF-1a.”
BackgroundTricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses
Choi, I., Son, H., & Baek, J.-H. (2021) · Life · doi:10.3390/life11010069 · Cited by 241
“In line with this, reduced levels of α-ketoglutarate were found to abolish PHD activity [16,53,69,71,72].”
BackgroundThe Role of Nogo and the Mitochondria–Endoplasmic Reticulum Unit in Pulmonary Hypertension
Sutendra, G., Dromparis, P., Wright, P., Bonnet, S., Haromy, A., Hao, Z., McMurtry, M. S., Michalak, M., Vance, J. E., Sessa, W. C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002194 · Cited by 240
Nitric Oxide in Macrophage Immunometabolism: Hiding in Plain Sight
Palmieri, E. M., McGinity, C., Wink, D. A., & McVicar, D. W. (2020) · Metabolites · doi:10.3390/metabo10110429 · Cited by 237
Mitochondria in Vascular Health and Disease
Dromparis, P., & Michelakis, E. D. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183804 · Cited by 236
Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer
Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00286 · Cited by 231
“For example, αKG increases the PHD affinity for oxygen and thus promotes HIF-1α hydroxylation and degradation even at low oxygen concentrations (17, 18).”
BackgroundSuccinate dehydrogenase: the complex roles of a simple enzyme
Huang, S., & Millar, A. H. (2013) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2013.02.007 · Cited by 224
“pseudohypoxia induction [32,33], sulphur metabolism and histone demethylation [31].”
BackgroundWaves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells
Smolková, K., Plecitá-Hlavatá, L., Bellance, N., Benard, G., Rossignol, R., & Ježek, P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.05.003 · Cited by 223
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
“So far, not many investigations of the anticancer activity of AKG have been carried out (Brière et al. 2005; Hou et al. 2014; MacKenzie et al. 2007; Matsumoto et al. 2006, 2009; Robinson et al. 1999; Rzeski et al. 2012; Tennant et al. 2009).”
BackgroundResultInfluentialYogev, O., Yogev, O., Singer, E., Shaulian, E., Goldberg, M., Fox, T. D., & Pines, O. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000328 · Cited by 220
Ebbesen, P., Pettersen, E. O., Gorr, T. A., Jobst, G., Williams, K., Kieninger, J., Wenger, R. H., Pastorekova, S., Dubois, L., Lambin, P., et al. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360902784425 · Cited by 218
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 217
Paulin, R., Dromparis, P., Sutendra, G., Gurtu, V., Zervopoulos, S., Bowers, L., Haromy, A., Webster, L., Provencher, S., Bonnet, S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.011 · Cited by 214
“We then exposed Sirt3KO-PASMCs to a cell-permeable form of a-KG (MacKenzie et al., 2007; Sutendra et al., 2013) and found that a-KG normalized the suppressed hydroxylation of HIF-1a, resulting in decreased HIF-1a nuclear levels, transcriptional activity, and target gene expression (Figure 2B).”
BackgroundMetabolic enzymes as oncogenes or tumor suppressors
Thompson, C. B. (2009) · New England Journal of Medicine · doi:10.1056/nejme0810213 · Cited by 213
Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
Thomas, L. W., & Ashcroft, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03039-y · Cited by 213
Metabolic reprogramming in renal cancer: Events of a metabolic disease
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K., & Pal, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188559 · Cited by 204
Sutendra, G., Dromparis, P., Paulin, R., Zervopoulos, S., Haromy, A., Nagendran, J., & Michelakis, E. D. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1059-4 · Cited by 204
Dong, L.-F., Jameson, V. J. A., Tilly, D., Cerny, J., Mahdavian, E., Marín-Hernández, A., Hernández-Esquivel, L., Rodríguez-Enríquez, S., Stursa, J., Witting, P. K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186643 · Cited by 200
Recurrent epimutation of SDHC in gastrointestinal stromal tumors
Killian, J. K., Miettinen, M., Walker, R. L., Wang, Y., Zhu, Y. J., Waterfall, J. J., Noyes, N., Retnakumar, P., Yang, Z., Smith, W. I., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009961 · Cited by 193
Targeting histone lysine demethylases — Progress, challenges, and the future
Thinnes, C. C., England, K. S., Kawamura, A., Chowdhury, R., Schofield, C. J., & Hopkinson, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.009 · Cited by 192
“Ester derivatives of TCA intermediates, 2HG and 2OG have been used as prodrugs in cellular functional studies because the parent di-acids have poor cell penetration [111].”
Potential Therapeutic Benefits of Strategies Directed to Mitochondria
Camara, A. K. S., Lesnefsky, E. J., & Stowe, D. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2788 · Cited by 194
Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia
Qutub, A. A., & Popel, A. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00060-08 · Cited by 191
The emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Sutendra, G., Dromparis, P., Kinnaird, A., Stenson, T. H., Haromy, A., Parker, J. M. R., McMurtry, M. S., & Michelakis, E. D. (2013) · Oncogene · doi:10.1038/onc.2012.198 · Cited by 184
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184
Metabolic Signaling to the Nucleus in Cancer
Campbell, S. L., & Wellen, K. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.015 · Cited by 181
HIF1A Reduces Acute Lung Injury by Optimizing Carbohydrate Metabolism in the Alveolar Epithelium
Eckle, T., Brodsky, K., Bonney, M., Packard, T., Han, J., Borchers, C. H., Mariani, T. J., Kominsky, D. J., Mittelbronn, M., & Eltzschig, H. K. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001665 · Cited by 165
“that succinate-mediated inhibition of PHD is competitive and is reversed by pharmacologically elevating intracellular a-ketoglutarate [56].”
BackgroundBurr, S. P., Costa, A. S. H., Grice, G. L., Timms, R. T., Lobb, I. T., Freisinger, P., Dodd, R. B., Dougan, G., Lehner, P. J., Frezza, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.015 · Cited by 164
“of 2-OG was unlikely to inhibit PHD activity, and prior reports show that cell-permeable 2-OG can overcome succinate-mediated inhibition of HIF1a prolyl hydroxylation (MacKenzie et al., 2007).”
BackgroundBayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
“HIF1α targets, including vascular endothelial growth factor (VEGF), erythropoietin (EPO), and glucose transporter1 (GLUT1), show activation on accumulation of TCA metabolites, and contribute to an increase in microvessel density [18,20,22-26].”
BackgroundKaadige, M. R., Looper, R. E., Kamalanaadhan, S., & Ayer, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901221106 · Cited by 162
“To test whether glutamine-dependent anapleurosis is required for repression of TXNIP, we treated BxPC-3 cells with the cell permeable 3-trif luoromethylbenzyl (TFMB)-KG (17).”
MethodState of the Science: An Update on Renal Cell Carcinoma
Jonasch, E., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 162
Philip, B., Ito, K., Moreno-Sanchez, R., & Ralph, S. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt209 · Cited by 161
Oncogenic regulation of tumor metabolic reprogramming
Tarrado-Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 161
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
“…and to paragangliomas linked to SDH defi- ciency (Gimenez-Roqueplo et al. 2001; Isaacs et al. 2005; Pollard et al. 2005; Selak et al. 2005, 2006; MacKenzie et al. 2007; Pollard et al. 2007; Sudarshan et al. 2009, 2011), although the paucity of relevant cell culture and mouse models has so far…”
Alpha-Ketoglutarate dietary supplementation to improve health in humans
Gyanwali, B., Lim, Z. X., Soh, J., Lim, C., Guan, S. P., Goh, J., Maier, A. B., & Kennedy, B. K. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.11.003 · Cited by 173
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 158
“At least in the context of SDH mutant cells, this inhibitory effect on dioxygenase activity can be ameliorated by addition of cell-permeable αKGanalogs (MacKenzie et al., 2007).”
BackgroundLow chorionic villous succinate accumulation associates with recurrent spontaneous abortion risk
Wang, X.-H., Xu, S., Zhou, X.-Y., Zhao, R., Lin, Y., Cao, J., Zang, W.-D., Tao, H., Xu, W., Li, M.-Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23827-0 · Cited by 158
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
German, N. J., Yoon, H., Yusuf, R. Z., Murphy, J. P., Finley, L. W. S., Laurent, G., Haas, W., Satterstrom, F. K., Guarnerio, J., Zaganjor, E., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.014 · Cited by 156
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 160
Dietary hyperglycemia, glycemic index and metabolic retinal diseases
Chiu, C.-J., & Taylor, A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.09.001 · Cited by 156
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
“It was initially reported that IDH1 mutations led to HIF-1 stabilization,37 but Koivunen et al. then showed that (R)2-HG efficiently inhibits a number of 2-OG-dependent dioxygenases, but does not inhibit PHDs.38 Instead, (R)2-HG was reported to be capable of promoting the activity of PHD1 and 2, and to a lesser extent…”
BackgroundInborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 146
“used cell-permeable esters of α-ketoglutarate to reactivate PHDs enzymatic activity and thus alleviated pseudohypoxia caused by the accumulation of succinate or fumarate [37, 38].”
BackgroundNon-invasive in vivo assessment of IDH1 mutational status in glioma
Chaumeil, M. M., Larson, P. E. Z., Yoshihara, H. A. I., Danforth, O. M., Vigneron, D. B., Nelson, S. J., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2013) · Nature Communications · doi:10.1038/ncomms3429 · Cited by 149
Salminen, A., Kauppinen, A., Hiltunen, M. O., & Kaarniranta, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.05.004 · Cited by 150
HIF-independent role of prolyl hydroxylases in the cellular response to amino acids
Durán, R. V., MacKenzie, E. D., Boulahbel, H., Frezza, C., Heiserich, L., Tardito, S., Bussolati, O., Rocha, S., Hall, M. N., & Gottlieb, E. (2013) · Oncogene · doi:10.1038/onc.2012.465 · Cited by 139
Self-citationTseng, C.-W., Kuo, W.-H., Chan, S.-H., Chan, H.-L., Chang, K.-J., & Wang, L.-H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2906 · Cited by 131
Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming
Zeng, W., Li, F., Jin, S., Ho, P., Liu, P.-S., & Xie, X. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02832-9 · Cited by 158
“α-KG alone is able to offset the HIF-1α activation induced by succinate or hypoxia [118, 119], and α-KG is a co-stimulator of JMJD3 while succinate is an inhibitor [51].”
BackgroundHepatic response to aluminum toxicity: Dyslipidemia and liver diseases
Mailloux, R. J., Lemire, J., & Appanna, V. D. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.07.009 · Cited by 131
“KG supplementation has been shown to trigger HIF-1α hydroxylation and degradation [38].”
BackgroundThe α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 141
“This resulted in the reversal of enhanced glycolysis and cell death [82, 89].”
BackgroundLncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect
Xiang, S., Gu, H., Jin, L., Thorne, R. F., Zhang, X. D., & Wu, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711257115 · Cited by 129
“In particular, α-KG functions as an electron donor to PHDs for prolyl hydroxylation, which is important for hydroxylation and degradation of HIF1α (26).”
BackgroundRalph, S. J., Moreno-Sánchez, R., Neuzil, J., & Rodríguez-Enríquez, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0566-7 · Cited by 126
Mitochondria as targets for chemotherapy
Gogvadze, V. G., Orrenius, S., & Zhivotovsky, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0323-0 · Cited by 140
Singh, R., Lemire, J., Mailloux, R. J., & Appanna, V. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002682 · Cited by 123
A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 120
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death
Tennant, D. A., Frezza, C., MacKenzie, E. D., Nguyen, Q., Zheng, L., Selak, M. A., Roberts, D. L., Dive, C., Watson, D. G., Aboagye, E. O., et al. (2009) · Oncogene · doi:10.1038/onc.2009.250 · Cited by 130
Benito, J., Shi, Y., Szymanska, B., Carol, H., Boehm, I., Lu, H., Konoplev, S. N., Fang, W., Zweidler‐McKay, P. A., Campana, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023108 · Cited by 130
The genetic and metabolic signature of oncocytic transformation implicates HIF1α destabilization
Porcelli, A. M., Ghelli, A., Ceccarelli, C., Lang, M., Cenacchi, G., Capristo, M., Pennisi, L. F., Morra, I., Ciccarelli, E., Melcarne, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp566 · Cited by 121
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 131
The role of mitochondria in pulmonary vascular remodeling
Dromparis, P., Sutendra, G., & Michelakis, E. D. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0670-x · Cited by 118
Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 126
“In renal cancer, the inactivating mutations of SDH or FH deficiency results in the subsequent accumulation of succinate or fumarate, respectively, thus, the inhibition of hypoxia-inducible factor (HIF) prolyl hydroxylases (HPH), which protect the stabilization of HIF and promote angiogenesis by increasing α-KG intake…”
Background
Metadata
- Authors
- MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E.
- Affiliations
- Cancer Research UK (GB)
- Tocris Cookson Ltd, Northpoint, Fourth Way, Avonmouth, Bristol BS11 8TA, United Kingdom
- University of Strathclyde (GB)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-05-01
- Volume
- 27
- Issue
- 9
- Pages
- 3282-3289
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1899954
- OpenAlex
- W2130757625
- Cited by
- 359
- References
- 31
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 8 · 2023: 16 · 2022: 10 · 2021: 30 · 2020: 23 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 22 · 2015: 18 · 2014: 23 · 2013: 23 · 2012: 16
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- succinate dehydrogenase deficiency, fumarate hydratase deficiency, pseudohypoxia, hypoxia-inducible factor-1α, prolyl hydroxylase inhibition, cancer therapy, succinic acid, fumarate
- MeSH terms
- Cell Line, Cell Membrane Permeability, Humans, Ketoglutaric Acids, Protein Binding, Succinate Dehydrogenase, Molecular Structure, Cell Hypoxia, Ubiquitin, Proteasome Endopeptidase Complex, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.